- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
High glycated albumin levels tied to risk of CVD and death in advanced-stage diabetic kidney disease patients
![High glycated albumin levels tied to risk of CVD and death in advanced-stage diabetic kidney disease patients High glycated albumin levels tied to risk of CVD and death in advanced-stage diabetic kidney disease patients](https://medicaldialogues.in/h-upload/2023/05/05/750x450_208867-glycated-albumin.webp)
China: A meta-analysis published in Diabetes, Obesity and Metabolism has shown an association between high glycated albumin (GA) and an increased risk of cardiovascular diseases (CVDs) and mortality in patients with and without dialysis.
Higher levels of HbA1c (haemoglobin A1c), the gold standard indicator of glycemic control, predicted all-cause and cardiovascular mortality in diabetes patients undergoing chronic hemodialysis. However, in patients with advanced-stage diabetic kidney disease (DKD), HbA1c values are underestimated due to unpredictable changes in the survival time of erythrocytes, leading to the unreliability of the HbA1c values.
Glycated albumin indicating average glucose levels during the preceding 2 to 3 weeks is preferable to HbA1c for evaluating glycemic control in chronic hemodialysis patients with diabetes because the erythrocytes' life span does not impact GA levels.
Previous studies have shown glycated albumin to be a more accurate measure of short-term blood sugar control in dialysis patients. Therefore, Huilei Zhao, The Third Hospital of Nanchang, Nanchang, China, and colleagues aimed to determine the relationship between GA and the risk of mortality and cardiovascular diseases in patients with and without dialysis.
For this purpose, the researchers searched cohort studies of associations between GA level and cardiovascular disease and mortality in online databases. The random effects model summarized the effect size, and the robust error meta-regression method determined the dose-response association.
Data from 17 cohort studies were included (12 were prospective and five were retrospective) comprising 80 024 participants.
The authors reported the following findings:
- Higher levels of GA were associated with increased risk of CV mortality [hazard ratio = 1.90], all-cause mortality (hazard ratio = 1.64), major adverse cardio-cerebral events (risk ratio = 1.41), coronary artery disease (odds ratio = 2.24) and stroke (risk ratio = 1.72).
- The dose-response analysis showed that GA levels were positively and linearly associated with the risk of CV mortality, all-cause mortality and coronary artery disease.
- Subgroup analysis revealed that high levels of GA were associated with the risk of CV and all-cause mortality, regardless of dialysis status, with significant differences between subgroups of dialysis.
"Our findings showed that high glycated albumin levels are linked with an increased risk of CVDs and mortality, regardless of dialysis status," the researchers concluded.
Reference:
Zhao, Huilei, et al. "Glycated Albumin and Risk of Cardiovascular Diseases and Mortality in Patients With and Without Dialysis: a Meta-analysis." Diabetes, Obesity & Metabolism, 2023.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751